Close Menu

NEW YORK – As healthcare payors and C-suite decision makers continue to insist on clinical utility and outcomes studies to justify the use of new diagnostics in microbiology, a new collaborative spirit is growing among stakeholders.

Under the auspices of the American Society of Microbiology (ASM), industry and lab representatives have come together to outline approaches to these necessary studies, and they will soon be meeting to develop a toolkit to stimulate and guide more published outcomes research — and potentially create a pool of funds to support diagnostic agnostic trials.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Dec
19
Sponsored by
Qiagen

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.